Active Ingredient(s): Tedizolid Phosphate
FDA Approved: * June 20, 2014
Pharm Company: * CUBIST PHARMS
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Sivextro Overview

Tedizolid (formerly torezolid, trade name Sivextro),[3] is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).[4]...

Read more Sivextro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Sivextro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tedizolid Phosphate
  • Injection: 200mg
  • Powder: 200mg/vial
  • Tablet: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Sivextro: (2 results)

Sorted by National Drug Code
  • 67919-040 Sivextro 200 mg Intravenous Powder, for Solution by Cubist Pharmaceuticals, Inc.
  • 67919-041 Sivextro 200 mg Oral Tablet, Coated by Cubist Pharmaceuticals, Inc.

Other drugs which contain Tedizolid Phosphate or a similar ingredient: (1 result)